Catalytic metalloporphyrin protects against paraquat neurotoxicity in vivo

Biomed Environ Sci. 2008 Jun;21(3):233-8. doi: 10.1016/S0895-3988(08)60035-5.

Abstract

Objective: To examine the neuroprotective effects of a novel manganese porphyrin, manganese (III) meso-tetrakis (N,N'-diethylimidazolium-2-yl) porphyrin (MnTDM), in the mouse model of Parkinson's disease (PD) induced by paraquat (PQ).

Methods: Male C57BL/6 mice were subcutaneously injected with either saline or PQ at 2-day intervals for a total of 10 doses, MnTDM was subcutaneously injected with the PQ 2 h before treatment. Performance on the pole and swim test were measured 7 days after the last injection and animals were sacrificed one day later. Levels of dopamine (DA) and its metabolites in the striatum were measured by high-performance liquid chromatography with an electrochemical detector (HPLC-ECD). Thiobarbituric acid (TBA) method was used to assay the lipid peroxidation product, malondialdehyde (MDA), and the number of tyrosine hydroxylase (TH) positive neurons was estimated using immunohistochemistry.

Results: Pretreatment with MnTDM significantly attenuated PQ-impaired behavioral performance, depleted dopamine content in striata, increased MDA, and dopaminergic neuron loss in the substantia nigra.

Conclusions: Oxidative stress plays an important role in PQ-induced neurotoxicity which can be potentially prevented by manganese porphyrin. These findings also propose a possible therapeutical strategy for neurodegenerative disorders associated with oxidative stress such as PD.

MeSH terms

  • Animals
  • Antioxidants / therapeutic use*
  • Antiparkinson Agents / therapeutic use*
  • Behavior, Animal / drug effects
  • Catalysis
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine / metabolism
  • Male
  • Malondialdehyde / metabolism
  • Metalloporphyrins / therapeutic use*
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / therapeutic use*
  • Paraquat
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Substantia Nigra / drug effects
  • Substantia Nigra / enzymology
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • AEOL 10150
  • Antioxidants
  • Antiparkinson Agents
  • Metalloporphyrins
  • Neuroprotective Agents
  • Malondialdehyde
  • Tyrosine 3-Monooxygenase
  • Paraquat
  • Dopamine